AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

MarketsPricingSign inSign up free

HUMAN NORMAL IMMUNOGLOBULIN

8 registrations across 4 African markets— 7 active

Markets with HUMAN NORMAL IMMUNOGLOBULIN

🇿🇦South Africa
3 registrations
3 active
🇹🇿Tanzania
2 registrations
2 active
🇿🇲Zambia
2 registrations
2 active
🇲🇼Malawi
1 registration
0 active

Recent registrations

Brand / ProductMarketHolderStatusExpires
Gamma I.V 2.5 Injection
Solution for Injection
🇿🇲ZambiaBharat Serums and Vaccines LimitedactiveJan 2030
Gamma 5 Injection
Solution for Injection
🇿🇲ZambiaBharat Serums and Vaccines LimitedactiveJan 2030
PRIVIGEN 25 ml🇿🇦South AfricaGen-Eye (Pty) LtdactiveOct 2028
PRIVIGEN 50 ml🇿🇦South AfricaGen-Eye (Pty) LtdactiveOct 2028
PRIVIGEN 100 ml🇿🇦South AfricaGen-Eye (Pty) LtdactiveOct 2028
GLOBUMAN 160M/ML INJECTION
INJECTION
🇲🇼Malawi—expiredJun 1997
GENSULIN N
Suspension for injection
🇹🇿TanzaniaBIOTON S.Aactive—
Globucel
liquid injection
🇹🇿TanzaniaIntas Pharmaceuticals Limitedactive—

HUMAN NORMAL IMMUNOGLOBULIN in Africa — Regulatory Overview

HUMAN NORMAL IMMUNOGLOBULIN is registered across 4 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Tanzania, Zambia, Malawi. AfricaRegulatory refreshes this data daily from official government sources.

Of the 8 registrations, 7 (88%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.